SynAct Pharma is a biotech company aiming at resolving inflammation by leveraging melanocortin biology. Our lead asset AP1189 is in phase 2 development for the treatment of rheumatoid arthritis. AP1189 is an immunomodulatory small molecule delivered as a once-daily tablet. The mode of action is selective melanocortin receptor type 1 and 3 agonism, making it first-in-class. Activation of these receptors results in reduced secretion of proinflammatory cytokines by neutrophils and in conversion of macrophages towards clearing away cellular debris in hyper-inflamed tissue – two effects that together induce resolution of inflammation. The Phase 2a BEGIN study in patients with rheumatoid arthritis reported very promising efficacy and safety results in November 2021 - next step is to open an IND with FDA to get advice on further development.
Due to the known Mode of Action, then AP1189 was also tested in COVID-19 positive patients with respiratory insufficiency. Results were reported in July 2021, demonstrating 4 days earlier respiratory recovery, 3 days earlier hospital discharge and more than 50% reduced risk of progressing to needing mechanical ventilation.
Company Details
- Employees
- 11
- Founded
- -
- Address
- Medicon Village Ab, Sheelevägen 2, Lund,se-223 81,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.synactpharma.com
- Keywords
- Inflammation, Melanocortins, COVID-19, Rheumatoid Arthritis, Nephrotic Syndrome, Biotechnology.
- HQ
- Lund
Synact Pharma Questions
Synact Pharma's website is http://www.synactpharma.com
Synact Pharma's LinkedIn profile is https://se.linkedin.com/company/synact-pharma
Synact Pharma has
11 employees.
View email and phone details for 11
employees at Synact Pharma.
Synact Pharma's industry is
Biotechnology Research
Synact Pharma's top competitors are
Stayble Therapeutics,
Resother Pharma,
Cereno Scientific,
Biostock - Connecting Innovation And Capital,
Tetra Pharm Technologies,
Irlab Therapeutics Ab,
Pila Pharma,
Alzinova Ab,
Toleranzia Ab,
Cantargia Ab.
Synact Pharma's categories are Biotechnology Research
Synact Pharma's founding year is 2013
